TPO and autoimmune thrombocytopenic purpura: This precaution is rooted in the heightened risk of severe SARS-CoV-2 infection associated with these medications.[47] Prior to the pandemic, Spanish guidelines recommended these immunosuppressants as third-line treatment options for ITP, followed by corticosteroids, intravenous immunoglobulin, thrombopoietin receptor agonists (TPO-RAs), and Syk inhibitors.